Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Fortress Biotech (FBIO) over the last 10 years, with Q3 2025 value amounting to $2.4 million.

  • Fortress Biotech's Change in Receivables rose 17537.06% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 9823.09%. This contributed to the annual value of -$4.5 million for FY2024, which is 6434.55% up from last year.
  • Fortress Biotech's Change in Receivables amounted to $2.4 million in Q3 2025, which was up 17537.06% from -$2.8 million recorded in Q2 2025.
  • Fortress Biotech's 5-year Change in Receivables high stood at $8.0 million for Q1 2022, and its period low was -$10.4 million during Q2 2023.
  • Over the past 5 years, Fortress Biotech's median Change in Receivables value was -$51000.0 (recorded in 2022), while the average stood at -$254315.8.
  • The largest annual percentage gain for Fortress Biotech's Change in Receivables in the last 5 years was 1417058.82% (2023), contrasted with its biggest fall of 1053855.42% (2023).
  • Fortress Biotech's Change in Receivables (Quarter) stood at -$8.5 million in 2021, then skyrocketed by 99.4% to -$51000.0 in 2022, then skyrocketed by 14170.59% to $7.2 million in 2023, then tumbled by 110.41% to -$747000.0 in 2024, then soared by 423.29% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, -$2.8 million for Q2 2025, and $8.0 million during Q1 2025.